Victor Vaz
Clinical FellowAbout
Research
Publications
2026
Distinct Genetic Alterations Drive Cushing Disease Versus Silent Corticotroph Adenomas
Paes T, Zhang Q, Borges CO, Mohan DR, Vaz V, Soares BS, Carroll RS, Kaiser UB, Smith TR, Bi WL, Meredith D, Lerario AM, Abreu AP. Distinct Genetic Alterations Drive Cushing Disease Versus Silent Corticotroph Adenomas. The Journal Of Clinical Endocrinology & Metabolism 2026, dgag229. DOI: 10.1210/clinem/dgag229.Peer-Reviewed Original ResearchAddressing Methodological Gaps: A Systematic Review and Meta-Analysis of Beetroot Juice and Exercise Capacity in Chronic Obstructive Pulmonary Disease
Chiappa G, Filho A, Sá J, Duarte A, Ferrari G, Chiappa A, de Araújo Morais L, Muller P, Puente-Maestu L, Santos F, Vieira R, Caixeta D, Aprigliano V, Vaz V. Addressing Methodological Gaps: A Systematic Review and Meta-Analysis of Beetroot Juice and Exercise Capacity in Chronic Obstructive Pulmonary Disease. Nutrition Reviews 2026, nuag013. PMID: 41996285, DOI: 10.1093/nutrit/nuag013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLiraglutide and Exenatide in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes
Santos P, Filho A, Aprigliano V, Duarte A, Ribeiro N, Lombardo K, Fajemiroye J, Buchholz A, Vaz V, Chiappa G. Liraglutide and Exenatide in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes. Pharmaceutics 2026, 18: 69. PMID: 41599176, PMCID: PMC12844791, DOI: 10.3390/pharmaceutics18010069.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
Pecci F, Thummalapalli R, Alden S, Ricciuti B, Alessi J, Elkrief A, Rizvi H, Wang X, Jeng M, Egger J, Vaz V, Barrichello A, Lamberti G, Di Federico A, Santo V, de Almeida G, Gandhi M, Clark P, Nishino M, Hellmann M, Schoenfeld A, Awad M. Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer. Clinical Cancer Research 2025, 31: 2413-2425. PMID: 40247431, PMCID: PMC12709584, DOI: 10.1158/1078-0432.ccr-24-2990.Peer-Reviewed Original ResearchTumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, Lotter W, Lindsay J, Santo V, Cortellini A, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico A, Makarem M, Gandhi M, Nguyen T, Haradon D, Vaz V, Johnson B, Debnath N, Wang Y, Kuang A, Saeed A, Radford M, Lovly C, Nebhan C, Pinato D, Rodig S, Schoenfeld A, Awad M, Alessi J, Naqash A. Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients. Clinical Lung Cancer 2025, 26: 288-298.e8. PMID: 40021433, DOI: 10.1016/j.cllc.2025.01.014.Peer-Reviewed Original Research
2024
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma
Vaz V, Gandhi M, Ricciuti B, Alessi J, Elkrief A, Ladanyi M, Vanderbilt C, Pecci F, Aldea M, Barrichello A, Saini A, Sholl L, Sands J, Awad M. Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma. JCO Precision Oncology 2024, 8: e2400394. PMID: 39374479, DOI: 10.1200/po-24-00394.Peer-Reviewed Original ResearchIntrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Di Federico A, Alden S, Smithy J, Ricciuti B, Alessi J, Wang X, Pecci F, Lamberti G, Gandhi M, Vaz V, Spurr L, Sholl L, Pfaff K, Rodig S, Li Y, Cherniack A, Nishino M, Awad M. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Annals Of Oncology 2024, 35: 902-913. PMID: 38950679, DOI: 10.1016/j.annonc.2024.06.014.Peer-Reviewed Original ResearchActivating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee J, Alessi J, Barrichello A, Vaz V, Lamberti G, Di Federico A, Gandhi M, Gazgalis D, Feng W, Jiang J, Baldacci S, Locquet M, Gottlieb F, Chen M, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel V, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist R, Iqbal S, Gandhi N, Elliott A, Vanderwalde A, C. P, Halmos B, Liu S, Che J, Schrock A, Drilon A, Jänne P, Awad M. Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors. Cancer Discovery 2024, 14: 1440-1456. PMID: 38564707, PMCID: PMC11294820, DOI: 10.1158/2159-8290.cd-23-1217.Peer-Reviewed Original ResearchGenomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello A, Gandhi M, Vaz V, Pangilinan A, Haradon D, Lee E, Gupta H, Pfaff K, Welsh E, Nishino M, Cherniack A, Weirather J, Dryg I, Rodig S, Sholl L, Sorger P, Santagata S, Umeton R, Awad M. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2024, 42: 1311-1321. PMID: 38207230, PMCID: PMC11095860, DOI: 10.1200/jco.23.00580.Peer-Reviewed Original Research
2023
Powassan Virus Infections: A Systematic Review of Published Cases
Kakoullis L, Vaz V, Kaur D, Kakoulli S, Panos G, Chen L, Behlau I. Powassan Virus Infections: A Systematic Review of Published Cases. Tropical Medicine And Infectious Disease 2023, 8: 508. PMID: 38133440, PMCID: PMC10747444, DOI: 10.3390/tropicalmed8120508.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements